DexCom, Inc. (NASDAQ:DXCM) Receives $99.82 Average Target Price from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has received a consensus recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $99.82.

Several equities analysts have recently weighed in on DXCM shares. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Cfra Research upgraded shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th.

DexCom Stock Performance

NASDAQ DXCM opened at $72.13 on Monday. The company has a market capitalization of $28.19 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom has a 52-week low of $62.34 and a 52-week high of $141.99. The company has a 50-day simple moving average of $82.96 and a 200 day simple moving average of $77.07.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts predict that DexCom will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC grew its stake in shares of DexCom by 6.1% in the 3rd quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company’s stock worth $392,000 after buying an additional 335 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after acquiring an additional 288,381 shares in the last quarter. Cerity Partners LLC grew its stake in shares of DexCom by 190.0% in the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock worth $4,026,000 after acquiring an additional 39,344 shares during the last quarter. Swedbank AB increased its holdings in shares of DexCom by 15.2% during the third quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock valued at $14,337,000 after acquiring an additional 28,289 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its holdings in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.